Camurus AB (publ) (STO:CAMX)
603.50
-0.50 (-0.08%)
At close: Dec 5, 2025
Camurus AB Revenue
Camurus AB had revenue of 567.07M SEK in the quarter ending September 30, 2025, with 18.24% growth. This brings the company's revenue in the last twelve months to 2.35B, up 39.37% year-over-year. In the year 2024, Camurus AB had annual revenue of 1.87B with 8.78% growth.
Revenue (ttm)
2.35B
Revenue Growth
+39.37%
P/S Ratio
15.29
Revenue / Employee
8.41M
Employees
256
Market Cap
35.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.87B | 150.73M | 8.78% |
| Dec 31, 2023 | 1.72B | 760.51M | 79.52% |
| Dec 31, 2022 | 956.34M | 355.77M | 59.24% |
| Dec 31, 2021 | 600.57M | 264.57M | 78.74% |
| Dec 31, 2020 | 336.00M | 230.39M | 218.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Swedish Orphan Biovitrum AB | 27.85B |
| Getinge AB | 35.85B |
| Sectra AB | 3.37B |
| Medicover AB | 25.67B |
| Asker Healthcare Group AB | 16.41B |
| BioArctic AB | 1.92B |
| AddLife AB | 10.53B |
| Elekta AB | 17.57B |
Camurus AB News
- 26 days ago - Camurus reports positive topline results for CAM2056, semaglutide monthly depot - PRNewsWire
- 27 days ago - Camurus AB (publ) (CAMRF) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Camurus AB (publ) 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 4 weeks ago - Camurus AB (FRA:7CA) Q3 2025 Earnings Call Highlights: Strong Profit Growth Amid Revenue ... - GuruFocus
- 4 weeks ago - Q3 2025 Camurus AB Earnings Call Transcript - GuruFocus
- 4 weeks ago - Camurus AB (publ) reports Q3 results - Seeking Alpha
- 6 months ago - Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients - PRNewsWire
- 6 months ago - Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins - PRNewsWire